Usefulness of hemoglobin and albumin as prognostic markers for highly active antiretroviral therapy for HIV-1 infection

Indian Journal of Medical Sciences

Volumn 65, Issue 7, 2011, Pages 286-296

  Chauhan, Neeraj K ^a   Vajpayee, Madhu ^a   Singh, Alpana ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Albumin; CD4+ T cell counts; hemoglobin; HIV 1; prognostic markers

Indexed keywords

ALBUMIN; HEMOGLOBIN;

ADULT; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPOALBUMINEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; DRUG MONITORING; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SERUM ALBUMIN; YOUNG ADULT;

EID: 84875527018     PISSN: 00195359     EISSN: 19983654     Source Type: Journal    
DOI: 10.4103/0019-5359.107389     Document Type: Article

References (30)

1. Anastos K, Barron Y, Miotti P, Weiser B, Young M, Hessol N, et al. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med 2002;162:1973-80
2. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001;286:2560-7
3. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, OShaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286:2568-77
4. Feldman JG, Burns DN, Gange SJ, Bacchetti P, Cohen M, Anastos K, et al. Serum albumin as a predictor of survival in HIV-infected women in the Womens Interagency HIV study. AIDS 2000;14:863-70
5. Mekonnen Y, Dukers NH, Sanders E, Dorigo W, Wolday D, Schaap A, et al. Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. AIDS 2003;17:815-9
6. Kumarasamy N, Mahajan AP, Flanigan TP, Hemalatha R, Mayer KH, Carpenter CC, et al. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr 2002;31:378-83
7. Mocroft A, Bofill M, Lipman M, Medina E, Borthwick N, Timms A, et al. CD8?, CD38+lymphocyte percent: A useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:158-62
8. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:54-7
9. Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;26:315-9
10. Semba RD, Shah N, Klein RS, Mayer KH, Schuman P, Gardner LI, et al. Highly active antiretroviral therapy associated with improved anemia among HIV-infected women. AIDS Patient Care STDS 2001;15:473-80
11. Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS 1999;13:943-50
12. Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, DArminio Monforte A, Hermans P, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study. J Infect Dis 2002;185:178-87
13. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, dArminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003;362:22-9
14. Kannangai R, Kandathil AJ, Ebenezer DL, Mathai E, Prakash AJ, Abraham OC, et al. Usefulness of alternate prognostic serum and plasma markers for antiretroviral therapy for human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2008;15:154-8
15. Sundaram M, Srinivas CN, Shankar EM, Balakrishnan P, Solomon S, Kumarasamy N. Cofactors for low serum albumin levels among HIV-infected individuals in Southern India. J Int Assoc Physicians AIDS Care (Chic) 2009;8:161-4
16. Mehta SH, Astemborski J, Sterling TR, Thomas DL, Vlahov D. Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses 2006;22:14-21
17. Olawumi HO, Olatunji PO. The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients. HIV Med 2006;7:351-5
18. Sabin CA, Griffioen A, Yee TT, Emery VC, Herrero-Martinez E, Phillips AN, et al. Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: A longitudinal study. Lancet 2002;360:1546-51
19. Sanne I, Mommeja-Marin H, Hinkle J, Bartlett JA, Lederman MM, Maartens G, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005;191:825-9
20. Shah S, Smith CJ, Lampe F, Youle M, Johnson MA, Phillips AN, et al. Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretroviral therapy era: Relationships with gender. HIV Med 2007;8:38-45
21. Bini EJ, Cohen J. Impact of protease inhibitors on the outcome of human immunodeficiency virus-infected patients with chronic diarrhea. Am J Gastroenterol 1999;94:3553-9
22. Maggi P, Larocca AM, Quarto M, Serio G, Brandonisio O, Angarano G, et al. Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2000;19:213-7
23. Tumbarello M, Tacconelli E, Donati KG, Citton R, Leone F, Spanu T, et al. HIV-associated bacteremia: How it has changed in the highly active antiretroviral therapy (HAART) era. J Acquir Immune Defic Syndr 2000;23:145-51
24. Kreuzer KA, Rockstroh JK, Jelkmann W, Theisen A, Spengler U, Sauerbruch T. Inadequate erythropoietin response to anaemia in HIV patients: Relationship to serum levels of tumour necrosis factor-alpha, interleukin-6 and their soluble receptors. Br J Haematol 1997;96:235-9
25. Sloand EM, Maciejewski J, Kumar P, Kim S, Chaudhuri A, Young N. Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells. Blood 2000;96:2735-9
26. Agarwal D, Chakravarty J, Chaube L, Rai M, Agrawal NR, Sundar S. High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res 2010;132:386-9
27. Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenal B, Lai AR, Saghayam S, et al. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS 2008;22:337-44
28. Isaakidis P, Raguenaud ME, Phe T, Khim SA, Kuoch S, Khem S, et al. Evaluation of a systematic substitution of zidovudine for stavudine-based HAART in a program setting in rural Cambodia. J Acquir Immune Defic Syndr 2008;49:48-54
29. Sundaram M, Saghayam S, Priya B, Venkatesh KK, Balakrishnan P, Shankar EM, et al. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India. Int J Infect Dis 2008;12:e61-6
30. Resino S, Bellon JM, Sanchez-Ramon S, Gurbindo D, Munoz-Fernandez MA. Clinical relevance of cytokine production in HIV-1 infection in children on antiretroviral therapy. Scand J Immunol 2000;52:634-40